Case Report: sustained five-year remission in eosinophilic granulomatosis with polyangiitis with intestinal perforation after surgery and rituximab-based therapy without glucocorticoid escalation - Scorecard - MDSpire
Advertisement
Case Report: sustained five-year remission in eosinophilic granulomatosis with polyangiitis with intestinal perforation after surgery and rituximab-based therapy without glucocorticoid escalation
Clinical Scorecard: Long-term Remission Achieved in Eosinophilic Granulomatosis with Polyangiitis Following Surgical Intervention and Rituximab Therapy Without Increased Glucocorticoid Use: A Case Study
At a Glance
Category
Detail
Condition
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Key Mechanisms
Systemic necrotizing vasculitis characterized by eosinophilic infiltration and granuloma formation.
Target Population
Patients with severe EGPA, particularly those with gastrointestinal involvement.
Care Setting
Clinical management of severe EGPA requiring surgical intervention.
Key Highlights
EGPA can present with severe gastrointestinal involvement, including intestinal perforation.
Rituximab (RTX) was used successfully for remission induction without increasing glucocorticoid doses.
Long-term remission was achieved over five years with minimal glucocorticoid exposure.
Guideline-Based Recommendations
Diagnosis
EGPA is diagnosed based on clinical criteria including eosinophilia and extrapulmonary manifestations.
Management
Standard treatment includes high-dose glucocorticoids combined with cyclophosphamide or rituximab.
Monitoring & Follow-up
Monitor eosinophil counts and inflammatory markers during treatment.
Risks
Increased risk of postoperative complications with glucocorticoid escalation.
Patient & Prescribing Data
A 63-year-old male with treatment-resistant EGPA and severe GI involvement.
Rituximab may serve as a viable GC-sparing option for severe EGPA.
Clinical Best Practices
Avoid glucocorticoid escalation in the perioperative setting to reduce postoperative risks.
Consider rituximab for patients with severe or treatment-resistant EGPA.
